By Len Zehrs Vital Therapies (NASDAQ:VTL) expects to report top line data from its ELAD pivotal study, known as VTL-308, in patients with severe alcoholic hepatitis (sAH), an acute form of liver failure, by the end of...
Tag - ELAD pivotal study
